151 related articles for article (PubMed ID: 17130630)
1. Potential reduced exposure products (PREPs) in industry trial testimony.
Wayne GF
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv90-7. PubMed ID: 17130630
[TBL] [Abstract][Full Text] [Related]
2. Tobacco manufacturers' defence against plaintiffs' claims of cancer causation: throwing mud at the wall and hoping some of it will stick.
Milberger S; Davis RM; Douglas CE; Beasley JK; Burns D; Houston T; Shopland D
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv17-26. PubMed ID: 17130620
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of tobacco industry retail marketing activities of reduced harm products.
Slater S; Giovino G; Chaloupka F
Nicotine Tob Res; 2008 Jan; 10(1):187-93. PubMed ID: 18188759
[TBL] [Abstract][Full Text] [Related]
4. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications.
Pederson LL; Nelson DE
Nicotine Tob Res; 2007 May; 9(5):525-34. PubMed ID: 17454709
[TBL] [Abstract][Full Text] [Related]
5. The Tobacco Deposition and Trial Testimony Archive (DATTA) project: origins, aims, and methods.
Davis RM; Douglas CE; Beasley JK
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv4-8. PubMed ID: 17130623
[TBL] [Abstract][Full Text] [Related]
6. Consumer awareness and attitudes related to new potential reduced-exposure tobacco products.
Parascandola M; Hurd AL; Augustson E
Am J Health Behav; 2008; 32(4):431-7. PubMed ID: 18092903
[TBL] [Abstract][Full Text] [Related]
7. Perceptions of industry responsibility and tobacco control policy by US tobacco company executives in trial testimony.
Chaiton M; Ferrence R; LeGresley E
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv98-106. PubMed ID: 17130631
[TBL] [Abstract][Full Text] [Related]
8. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes.
Dunsby J; Bero L
Tob Control; 2004 Dec; 13(4):362-9. PubMed ID: 15564619
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of the third wave of tobacco litigation in the United States, 1994-2005.
Douglas CE; Davis RM; Beasley JK
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv9-16. PubMed ID: 17130629
[TBL] [Abstract][Full Text] [Related]
10. The role of tobacco advertising and promotion: themes employed in litigation by tobacco industry witnesses.
Goldberg ME; Davis RM; O'Keefe AM
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv54-67. PubMed ID: 17130625
[TBL] [Abstract][Full Text] [Related]
11. No sisyphean task: how the FDA can regulate electronic cigarettes.
Paradise J
Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
[TBL] [Abstract][Full Text] [Related]
12. Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products.
Biener L; Bogen K; Connolly G
Tob Control; 2007 Oct; 16(5):306-11. PubMed ID: 17897988
[TBL] [Abstract][Full Text] [Related]
13. A Premiere example of the illusion of harm reduction cigarettes in the 1990s.
Pollay RW; Dewhirst T
Tob Control; 2003 Sep; 12(3):322-32. PubMed ID: 12958396
[TBL] [Abstract][Full Text] [Related]
14. Methods used in internal industry clinical trials to assess tobacco risk reduction.
Rees VW; Kreslake JM; O'Connor RJ; Cummings KM; Parascandola M; Hatsukami D; Shields PG; Connolly GN
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3196-208. PubMed ID: 19959673
[TBL] [Abstract][Full Text] [Related]
15. Whither tobacco product regulation?
McNeill A; Hammond D; Gartner C
Tob Control; 2012 Mar; 21(2):221-6. PubMed ID: 22345253
[TBL] [Abstract][Full Text] [Related]
16. Historians' testimony on "common knowledge" of the risks of tobacco use: a review and analysis of experts testifying on behalf of cigarette manufacturers in civil litigation.
Kyriakoudes LM
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv107-16. PubMed ID: 17130618
[TBL] [Abstract][Full Text] [Related]
17. A strategy for controlling the marketing of tobacco products: a regulated market model.
Borland R
Tob Control; 2003 Dec; 12(4):374-82. PubMed ID: 14660771
[TBL] [Abstract][Full Text] [Related]
18. How the health belief model helps the tobacco industry: individuals, choice, and "information".
Balbach ED; Smith EA; Malone RE
Tob Control; 2006 Dec; 15 Suppl 4(Suppl 4):iv37-43. PubMed ID: 17130622
[TBL] [Abstract][Full Text] [Related]
19. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry.
Tong EK; England L; Glantz SA
Pediatrics; 2005 Mar; 115(3):e356-66. PubMed ID: 15741361
[TBL] [Abstract][Full Text] [Related]
20. Taking ad-Vantage of lax advertising regulation in the USA and Canada: reassuring and distracting health-concerned smokers.
Anderson SJ; Pollay RW; Ling PM
Soc Sci Med; 2006 Oct; 63(8):1973-85. PubMed ID: 16843578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
